Search Courses

Journal SAM 43-4B: Fine-tuning the Normal Tissue Objective in Eclipse for Lung Stereotactic Body Radiation Therapy

Course Details

CEUs: 2.5

Available Until: 12/31/2019

Non-Member Price: $87.50

Member Price: $50.00

Member PLUS Price: $50.00

Add to My Courses

Once you have exceeded your annual free credit allowance you will be prompted to pay a per-credit fee.

Courses purchased using your credit allowance are non-refundable and need to be completed before their expiration date

View your annual credit allowance here.

James P. Bell, M.S., R.T.T.,* Pretesh Patel, M.D.,† Kristin Higgins, M.D.,†
MarkW. McDonald, M.D.,‡ and Justin Roper, Ph.D., D.A.B.R.‡

*Department of Radiation Oncology, Simmons Comprehensive Cancer Center at the University of Texas Southwestern Medical Center, Dallas, TX;
†Winship Cancer Institute of Emory University, 1356 Clifton Road NE, Building C, Atlanta, Georgia 30322; and ‡Hospital Corporation of America,
Sarah Cannon Cancer Center, Department of Radiation Oncology, 2410 Patterson Street, Basement Level, Nashville, TN 37203

The purpose of this study was to characterize the effects of the normal tissue objective (NTO) on lung stereotactic body radiation therapy (SBRT) dose distributions. The NTO is a spatially varying constraint used in Eclipse to limit dose to normal tissues by steepening the dose gradient. However, the multitude of potential NTO setting combinations challenges optimal NTO tuning. In the present study, a broad range of NTO settings are investigated for lung SBRT treatment planning with volumetric modulated arc therapy(VMAT). Ten prior lung SBRT cases were replanned using NTO priorities of 1, 50, 100, 200, 500, and 999 in combination with fall-off values of 0.01, 0.05, 0.10, 0.15, 0.20, 0.30, 0.50, 1.00, and 5.00 mm−1 and the automatic NTO. NTO distances to planning target volume (PTV), start dose, and end dose were 1 mm, 100%, and 10%, respectively, for all 600 plans. Prescription dose covered 95% of the PTV. The following metrics were recorded: conformity index (CI), ratio of the 50% prescription isodose volume to PTV (R50%), maximum dose 2 cm away from PTV (D2cm), lung volume of ≥20 Gy (V20Gy), maximum PTV dose (PTVmax), and monitor units (MUs). Differences between prior plans and NTO plans were evaluated using the Wilcoxon signed-rank test. Different combinations of NTO settings resulted in wide-ranging plan quality metrics: CI (1.00 to 1.54), R50% (3.95 to 7.57), D2cm (33.4% to 67.9%), V20Gy (1.66% to 2.75%), MU (1.81 cGy−1 to 4.69 cGy−1), and PTVmax (118% to 175%). Although no settings were optimal for all metrics, a fall-off of 0.15mm−1 and a priority of 500 best satisfied institutional criteria. Compared with prior plans, NTO plans resulted in significantly lower R50% (4.00 vs 4.35, p = 0.002), lower V20Gy (1.22% vs 1.32%, p = 0.006), and higher PTVmax (138% vs 122%, p = 0.002). All of the prior and well-tuned NTO plans met Radiation Therapy Oncology Group (RTOG) 0813 guidelines. Lung SBRT dose distributions were characterized across a range of NTO settings. NTO plans with well-tuned settings compared favorably with prior plans.